Eli Lilly CEO Dave Ricks told CNBC that Medicare’s decision to cover obesity drugs later this year will “change the game” for the company’s experimental oral weight-loss pill, orforglipron. Ricks said Lilly expects coverage “immediately following launch” in Q2, unlocking access for millions of patients who currently pay cash for competitor GLP-1 injections. He noted that early adopters of obesity drugs are almost universally new to the class, expanding the total addressable market. Lilly is ramping commercial readiness with field teams and patient support programs to coincide with the policy change under the drug-pricing agreements struck last November.

On Mad Money, host Jim Cramer identified three key drivers for Lilly’s stock momentum: tirzepatide’s sales ramp in diabetes, the upcoming orforglipron launch, and the potential late-stage readouts for the dual-agonist retatrutide injection. Cramer highlighted the premium valuation relative to peers, underscoring high investor expectations for consistent double-digit revenue growth. He expects Q4 results due Feb. 4 to show tirzepatide revenue growth exceeding 80% year-over-year, setting up a strong 2026 guidance range above consensus.

Lilly announced plans to invest $3.5 billion in a new Lehigh Valley, Pennsylvania manufacturing facility dedicated to next-generation obesity injections, including retatrutide. Construction is slated to begin this year, with operations targeted by 2031. The site will employ 850 full-time staff and 2,000 construction workers, adding to Lilly’s ongoing $27 billion U.S. expansion. The additional capacity is designed to prevent repeat shortages experienced in 2024 and to support simultaneous launches of orforglipron and future triple-agonist therapies.

In 2025 Lilly more than doubled its U.S. promotion spend for its obesity and diabetes portfolio to roughly $214 million, compared with zero investment two years earlier. That spend supported Zepbound and Mounjaro detailing to physicians and direct-to-consumer outreach in states allowing prescription drug advertising. According to IQVIA, Lilly captured about 60% of U.S. obesity prescriptions in 2025, up from 48% the prior year, driven by clinical data showing Zepbound users achieved a 47% greater mean weight loss versus competitors in head-to-head trials.